Anti‐Melanoma Differentiation‐Associated Gene 5 Antibody‐Positive Interstitial Lung Disease, Induced by Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma
IJU Case Reports · 2026-03 · 9 (2)
DOI: 10.1002/iju5.70148 ↗Kurz gefasst
Fachartikel in der Zeitschrift IJU Case Reports, online erschienen am 05.02.2026. Verfasst von Akira Saito und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Saiseikai Kawaguchi General Hospital Saitama Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Anti‐melanoma differentiation‐associated gene 5 antibody‐positive interstitial lung disease is a rare but fatal adverse event following immune checkpoint inhibitor treatment for cancers. However, such cases have not been previously reported in patients with urothelial carcinoma. Case Presentation A 79‐year‐old Japanese woman with advanced unresectable bladder cancer was treated with first‐line enfortumab vedotin plus pembrolizumab. During the second treatment cycle, interstitial lung disease developed, and the patient immediately received steroid pulse therapy. As interstitial lung disease rapidly progressed after the initiation of steroid pulse therapy, immunosuppressive treatment with cyclophosphamide and tacrolimus was added. However, interstitial lung disease did not improve, and the patient died on day 54 after initiating treatment. Detailed antibody examination revealed positive anti‐melanoma differentiation‐associated gene 5 antibodies.
Conclusion
We report the first case of anti‐melanoma differentiation‐associated gene 5 antibody‐positive interstitial lung disease induced by enfortumab vedotin plus pembrolizumab in a patient with advanced urothelial carcinoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology Saiseikai Kawaguchi General Hospital Saitama Japan.
- Department of Urology Tokyo Women's Medical University Tokyo Japan.
ORCID-Profile: Toshio Takagi
Zitieren
APA
Saito, A., Ishihara, H., Kondo, H., Takagi, T., & Hashimoto, Y. (2026). Anti‐Melanoma Differentiation‐Associated Gene 5 Antibody‐Positive Interstitial Lung Disease, Induced by Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma. IJU Case Reports, 9(2). https://doi.org/10.1002/iju5.70148
Vancouver
Saito A, Ishihara H, Kondo H, Takagi T, Hashimoto Y. Anti‐Melanoma Differentiation‐Associated Gene 5 Antibody‐Positive Interstitial Lung Disease, Induced by Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma. IJU Case Reports. 2026;9(2). doi:10.1002/iju5.70148
BibTeX
@article{Saito2026,
author = {Saito, Akira and Ishihara, Hiroki and Kondo, Hanae and Takagi, Toshio and Hashimoto, Yasunobu},
title = {Anti‐Melanoma Differentiation‐Associated Gene 5 Antibody‐Positive Interstitial Lung Disease, Induced by Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma},
journal = {IJU Case Reports},
year = {2026},
volume = {9},
number = {2},
doi = {10.1002/iju5.70148}
}
EUVIMED